TABLE 1.
Subject characteristics
| Study subject | Statusa | CD4 countb (cells/μl) | Viral loadc (RNA copies/ml) | HLA class I designation (A1/A2/B1/B2/C1/C2)d |
|---|---|---|---|---|
| Controllers | ||||
| 1 | EC | 809 | <50 | A*03/A*31/B*27/B*57/C*02/C*12 |
| 2 | EC | 1,211 | <50 | A*02/A*03/B*13/B*18/C*06/C*07 |
| 3 | EC | 540 | <50 | A*02/A*11/B*35/B*57/C*04/C*06 |
| 4 | EC | 603 | <50 | A*02/ND/B*13/B*49/C*06/C*07 |
| 5 | EC | 643 | <50 | A*24/A*31/B*27/B*27/C*02/C*02 |
| 6 | EC | 1,389 | <50 | A*11/A*31/B*15/B*15/C*03/C*04 |
| 7 | EC | 1,916 | <50 | A*01/A*24/B*08/B*35/C*04/C*07 |
| 8 | VC | 523 | 246 | A*01/A*26/B*49/B*57/C*06/C*07 |
| 9 | VC | 784 | 125 | A*24/A*25/B*39/B*57/C*06/C*12 |
| 10 | VC | 580 | 432 | A*29/A*32/B*44/B*44/C*05/C*16 |
| 11 | VC | 747 | 250 | A*01/A*03/B*27/B*57/C*02/C*06 |
| 12 | VC | 570 | 386 | A*02/A*03/B*18/B*07/C*07/C*12 |
| 13 | VC | 702 | 163 | A*01/A*02/B*38/B*57/C*06/C*12 |
| 14 | VC | 790 | 191 | A*11/A*26/B*35/B*58/C*04/C*14 |
| 15 | VC | 1,181 | 430 | A*03/A*68/B*13/B*56/C*06/C*07 |
| Median | 747 | 125 | ||
| Progressors | ||||
| 1 | TP | 349 | 22,730 | A*01/A*01/B*08/B*08/C*07/C*07 |
| 2 | TP | 550 | 286,000 | ND |
| 3 | DP | 441 | 78,400 | A*01/A*02/B*15/B*57/C*03/C*06 |
| 4 | TP | 522 | 39,550 | A*03/A*24/B*35/B*44/C*02/C*04 |
| 5 | TP | 510 | 60,000 | A*02/A*03/B*07/B*44/C*05/C*07 |
| 6 | TP | 175 | 115,240 | A*24/A*25/B*15/B*58/C*04/C*07 |
| 7 | TP | 440 | 622,800 | A*01/A*01/B*08/B*40/C*03/C*07 |
| 8 | TP | 371 | 217,200 | A*11/A*31/B*08/B*08/C*07/C*07 |
| 9 | TP | 407 | 3,455 | A*02/A*33/B*35/B*44/C*04/C*16 |
| 10 | TP | 340 | 23,750 | ND |
| 11 | TP | 317 | 8,606 | A*23/A*30/B*08/B*42/C*07/C*17 |
| 12 | TP | 448 | 153,286 | A*01/A*01/B*08/B*08/C*07/C*07 |
| 13 | TP | 575 | 24,224 | A*03/A*30/B*35/B*57/C*04/C*07 |
| 14 | TP | 416 | 23,279 | A*68/A*74/B*14/B*57/C*07/C*08 |
| 15 | TP | 500 | 9,333 | A*02/A*32/B*08/B*55/C*03/C*07 |
| Median | 440 | 39,550 |
a
VC, viremic controller; EC, elite controller; TP, typical progressor; DP, delayed progressor. DP refers to an individual who previously was a controller and later progressed. At the time of study, this individual had a viral load > 10,000 copies/ml compared to that determined for the prior year.
b
Data represent CD4 counts within 4 weeks of sample collection.
c
Data represent viral loads on the day of sample collection for assays (progressors were defined as having a median viral load >10,000 in the past year).
d
B*27 and B*57 alleles are shown in bold. ND, not determined.